Sanofi snubs Allergan, Allergan snubs Valeant

Share this article:

Allergan has told Valeant to go packing. The LA Times reports that the Botox maker has told acquisition-minded Valeant that the $46 billion being offered undervalues the company. Allergan also said the deal includes significant shareholder risk.

“We question how long Valeant would achieve the level of cost cuts it is proposing without harming the long-term viability and growth trajectory of our business,” Allergan CEO David Pyott wrote in a letter to Valeant, the Times reported.

Monday's refusal follows reports by Bloomberg on Friday that both Sanofi and Johnson & Johnson told the Botox manufacturer they had no interest in buying up its business. Allergan's reported solicitation would be a way to short-circuit Valeant's takeover attempt.

Bloomberg notes that acquiring Allergan means taking on businesses that include neurologic, dermatological and urological products, which could mean new businesses acquirers don't already have. Bloomberg notes that this would mean these companies would be diversifying, which “runs counter to what many drug companies are doing."

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.